> Ewing, NJ-based Redpointe Bio is cutting 11 workers - 44 percent of its staff and announced plans to examine its strategic options. Redpoint Bio release
> The New York Times took a close look at the biopharma industry in New Jersey, noting the shrinking fortunes of its big pharma residents. But they found a distinct bright spot in biomedical research work, which has been thriving in the state. Report
> Can-Fite BioPharma announced that its 80-patient Phase II clinical study using CF101 to treat patients with moderate to severe Dry Eye Syndrome had successfully met its primary efficacy endpoint. Release
> Seattle-based start-up Xori has pocketed $2.1 million from a $4.5 million round. Report
> Pfizer has extended its collaboration pact with Monogram Biosciences. Release
> Clinical Trials & Surveys Corp. will provide Johns Hopkins University with its StudyCTMS clinical trials management software and data quality services for less than $50,000. That's "significantly less than it would cost to hire a CRO to complete the same work," according to an announcement. Report
> An IDC study shows that the number of hours spent by "information workers" on email and other computer-based activities hasn't changed much since the global research company first started collecting data on the topic in 2001. Report
> OpenClinica Enterprise will be the electronic data capture and clinical data management solution for the Abuja heart study, a long-term effort involving as many as 10,000 patients from multiple sites across Nigeria. Report
And Finally... The New York Times looks at the hodgepodge of rules and regulations that govern the compassionate use of experimental therapies. Despite some amazing advances in various disease areas, dying patients are often left with few options. Article